Vbi Vaccines Stock Return On Asset
| VBIV Stock | USD 0.60 0.03 4.76% |
VBI Vaccines fundamentals help investors to digest information that contributes to VBI Vaccines' financial success or failures. It also enables traders to predict the movement of VBI Stock. The fundamental analysis module provides a way to measure VBI Vaccines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VBI Vaccines stock.
Return On Assets is likely to drop to -1.12 in 2024. VBI | Return On Asset |
VBI Vaccines Company Return On Asset Analysis
VBI Vaccines' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current VBI Vaccines Return On Asset | -0.29 |
Most of VBI Vaccines' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VBI Vaccines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
VBI Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for VBI Vaccines is extremely important. It helps to project a fair market value of VBI Stock properly, considering its historical fundamentals such as Return On Asset. Since VBI Vaccines' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of VBI Vaccines' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of VBI Vaccines' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
VBI Total Assets
Total Assets |
|
Based on the latest financial disclosure, VBI Vaccines has a Return On Asset of -0.2857. This is 96.73% lower than that of the Biotechnology sector and 98.79% lower than that of the Health Care industry. The return on asset for all United States stocks is 104.07% higher than that of the company.
VBI Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VBI Vaccines' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VBI Vaccines could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics of similar companies.VBI Vaccines is currently under evaluation in return on asset category among related companies.
VBI Fundamentals
| Return On Equity | -2.59 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (14.49) % | ||||
| Current Valuation | 47.37 M | ||||
| Shares Outstanding | 28.43 M | ||||
| Shares Owned By Insiders | 7.66 % | ||||
| Shares Owned By Institutions | 11.37 % | ||||
| Number Of Shares Shorted | 289.12 K | ||||
| Price To Earning | (3.79) X | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 2.02 X | ||||
| Revenue | 8.68 M | ||||
| Gross Profit | (10.19 M) | ||||
| EBITDA | (53.32 M) | ||||
| Net Income | (92.84 M) | ||||
| Cash And Equivalents | 82.41 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 53.04 M | ||||
| Debt To Equity | 0.32 % | ||||
| Current Ratio | 2.29 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (60.88 M) | ||||
| Short Ratio | 3.78 X | ||||
| Earnings Per Share | (6.03) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 131 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 18.02 M | ||||
| Total Asset | 86.95 M | ||||
| Retained Earnings | (582.45 M) | ||||
| Working Capital | (39.51 M) | ||||
| Current Asset | 7.89 M | ||||
| Current Liabilities | 3.03 M | ||||
| Net Asset | 86.95 M |
About VBI Vaccines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VBI Vaccines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VBI Vaccines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VBI Vaccines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:Check out VBI Vaccines Piotroski F Score and VBI Vaccines Altman Z Score analysis. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 0.558 | Quarterly Revenue Growth 1.911 | Return On Assets (0.29) | Return On Equity (2.59) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.